COST-EFFECTIVENESS ANALYSIS OF ADDING PIOGLITAZONE TO INSULIN REGIMEN IN TYPE2 DIABETES IN IRAN

被引：0
|
作者：
Davari, M. [1 ]
Khorasani, E. [1 ]
Shojaei, Savari R. [1 ]
Sari, Akbari A. [2 ]
Saiyarsarai, P. [3 ]
机构：
[1] Univ Tehran Med Sci, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Publ Hlth, Tehran, Iran
[3] Univ Tehran Med Sci, Dept Pharmacoecon & Pharmaceut Management, Fac Pharm, Tehran, Iran
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.774
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB69
引用
收藏
页码：S129 / S130
页数：3
相关论文
共 50 条
  • [31] Cost-Effectiveness Analysis on Pioglitazone Add-On Therapy to Patients Failing Insulin
    Gschwend, M. H.
    Beaudet, A.
    Heddaeus, H.
    Lange, M.
    Kremer-Koenig, J.
    Landers, B.
    Schlaeger, C.
    Sandtmann, R.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2011, 16 (06): : 355 - 362
  • [32] Cost-effectiveness of treatment of type 2 diabetes
    Eastman, RC
    DIABETES CARE, 1998, 21 (03) : 464 - 465
  • [33] The cost-effectiveness of screening for type 2 diabetes
    Engelgau, MM
    Narayan, KMV
    Thompson, TJ
    Boyle, JP
    Williamson, DF
    Manninen, DL
    Dong, FB
    Orians, CE
    Dasbach, EJ
    Teutsch, SM
    Eastman, R
    Herman, WH
    Songer, TJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (20): : 1757 - 1763
  • [34] Cost-Effectiveness of Dulaglutide Versus Liraglutide for Management of Type 2 Diabetes Mellitus in Iran
    Ekhlasi, Mahna
    Taheri, Saeed
    Yousefi, Nazila
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 32 : 54 - 61
  • [35] COST-EFFECTIVENESS OF ADDING A PHARMACIST TO THE PRIMARY CARE TEAM FOR THE MANAGEMENT OF TYPE 2 DIABETES PATIENTS
    Yu, J.
    Shah, B.
    Ip, E. J.
    Chan, J.
    VALUE IN HEALTH, 2012, 15 (04) : A181 - A181
  • [36] Cost-effectiveness analysis of insulin detemir compared to NPH insulin in patients with type-2 diabetes in the United Kingdom
    Smith, I
    Palmer, AJ
    Roze, S
    Kennedy-Martin, T
    VALUE IN HEALTH, 2004, 7 (06) : 735 - 736
  • [37] Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
    Marc Evans
    Barrie Chubb
    Jens Gundgaard
    Diabetes Therapy, 2017, 8 : 275 - 291
  • [38] Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
    Evans, Marc
    Chubb, Barrie
    Gundgaard, Jens
    DIABETES THERAPY, 2017, 8 (02) : 275 - 291
  • [39] Adding Pioglitazone to Insulin Containing Regimens in Type 2 Diabetes: Systematic Review and Meta-Analysis
    Clar, Christine
    Royle, Pamela
    Waugh, Norman
    PLOS ONE, 2009, 4 (07):
  • [40] Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes
    Niall J. Davison
    Nicole L. Guthrie
    Sarah Medland
    Paul Lupinacci
    Robert J. Nordyke
    Mark A. Berman
    Advances in Therapy, 2024, 41 : 806 - 825
12345